Strasbourg, France-based G Protein-Coupled Receptors (GPCR) pioneer Domain Therapeutics has expanded a research collaboration with New York’s Pfizer (NYSE: PFE).
Domain, which has teams working in both France and Canada, is focused on the discovery and development of new drugs in immuno-oncology, neurology and rare diseases.
The collaboration aims to profile downstream signaling pathways of a set of GPCRs potentially involved across multiple therapeutic areas.
Domain is eligible to receive unspecified upfront payments as well as R&D support, plus as potential discovery and milestone payments for future Pfizer programs which result from the work.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze